Replimune Group, Inc. (NASDAQ:REPL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on February 03, 2026.
The Healthcare company reported Q0 revenue of .
Replimune Group, Inc.'s stock currently trades at $7.38 with a market capitalization of $774.6M.